241 reports of this reaction
1.4% of all GEFITINIB reports
#17 most reported adverse reaction
PLEURAL EFFUSION is the #17 most commonly reported adverse reaction for GEFITINIB, manufactured by AstraZeneca Pharmaceuticals LP. There are 241 FDA adverse event reports linking GEFITINIB to PLEURAL EFFUSION. This represents approximately 1.4% of all 17,300 adverse event reports for this drug.
Patients taking GEFITINIB who experience pleural effusion should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PLEURAL EFFUSION is a less commonly reported adverse event for GEFITINIB, but still significant enough to appear in the safety profile.
In addition to pleural effusion, the following adverse reactions have been reported for GEFITINIB:
The following drugs have also been linked to pleural effusion in FDA adverse event reports:
PLEURAL EFFUSION has been reported as an adverse event in 241 FDA reports for GEFITINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
PLEURAL EFFUSION accounts for approximately 1.4% of all adverse event reports for GEFITINIB, making it a notable side effect.
If you experience pleural effusion while taking GEFITINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.